Surfactant nebulisation — Competitive Intelligence Brief

Surfactant nebulisation (Surfactant nebulisation) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Pulmonary surfactant replacement therapy. Area: Respiratory/Pulmonology.

phase 3 Pulmonary surfactant replacement therapy Respiratory/Pulmonology Small molecule

Target snapshot

Surfactant nebulisation (Surfactant nebulisation) — University of Zurich. Surfactant nebulisation delivers pulmonary surfactant directly to the lungs via inhalation to improve gas exchange and reduce respiratory distress.

Comparator set (2 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Surfactant nebulisation TARGET	Surfactant nebulisation	University of Zurich	phase 3	Pulmonary surfactant replacement therapy
Bolus surfactant	Bolus surfactant	Zekai Tahir Burak Women's Health Research and Education Hospital	marketed	Pulmonary surfactant replacement therapy
Poractant alfa (Curosurf®)	Poractant alfa (Curosurf®)	Chiesi Farmaceutici S.p.A.	marketed	Pulmonary surfactant replacement therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Pulmonary surfactant replacement therapy class)

1. Chiesi Farmaceutici S.p.A. · 1 drug in this class
2. University of Zurich · 1 drug in this class
3. Zekai Tahir Burak Women's Health Research and Education Hospital · 1 drug in this class